WNTresearch
WNTresearch - WNT researchWNTresearchWNTresearchWNTresearch

WNT research

  • WntResearch
    • About WntResearch
    • Business concept and strategies
    • market Potential
    • Interview with the founder
    • History
    • Scientific advisors
  • Pipeline
    • Foxy-5
      • Phase 1 study
      • Phase 2 study
    • Articles
    • metastases
    • WNT signaling
    • Partners
      • Allucent
      • Biovica
      • SAGA diagnostics
      • The Sage Group
    • Box-5
    • Patents
  • Investor
    • Financial reports
    • Warrants series 2021/2023
    • Share issues
      • Rights issue 2022
    • The Share
    • presentations
    • Financial calendar
  • NEWS
    • Press Releases
    • Subscribe
  • Corporate Governance
    • Nomination committee
    • General meetings
    • Management
    • Board
    • Articles of association
  • Contact
  • English
    • Swedish

Blog Grid View

WNTresearch   →  Blog Grid View

Blog Grid View

Author By Jakob IvarssonPosted on February 5, 2021February 5, 2021

Extraordinary General Meeting on Wednesday, March 10

Link...
Read More
Author By KatherinePosted on October 27, 2020October 27, 2020

BioStock publishes interview with acting CEO!

Link...
Read More
Author By DavidPosted on October 1, 2020October 1, 2020

Anders Rabbe is appointed acting CEO

Link...
Read More
Author By DavidPosted on September 24, 2020September 24, 2020

BioStock publishes interview with CEO Peter Morsing

Link...
Read More
Author By DavidPosted on July 9, 2020July 9, 2020

BioStock publishes summer interview with CEO Peter Morsing

Link...
Read More
Author By DavidPosted on April 17, 2020April 17, 2020

Wntresearch publishes quarterly report Q1 2020

Link...
Read More
Author By DavidPosted on April 15, 2020April 15, 2020

CEO interview about status in ongoing phase 2-study

Link...
Read More
Author By DavidPosted on October 1, 2019October 9, 2019

Biostock interviews the CEO

...
Read More
Author By DavidPosted on August 8, 2019October 9, 2019

WntResearch increases resources for out-licensing Foxy-5

Link...
Read More

A new approach to fight tumour spread!
Foxy-5 is a unique drug candidate:
Significant medical need, first-in-class, unique mode of action, excellent pharmacokinetics, strong preclinical efficacy data, favourable safety profile

QUICK LINKS

  • Phase 2 study
  • Press Releases
  • shares

Subscribe

    

Copyright © All rights reserved.